Abstract

Liquidity transformation and Eurosystem credit operations

Retrieved on: 
Thursday, April 25, 2024
Appendix, Central bank, Interaction, A.1, Research Papers in Economics, Coincidence, ACC, Style (visual arts), Policy, CQS, PDF, Next, PIGS (economics), R2, ECB, Risk, L2, ABS, Section 4, Social science, E52, JEL, Section 3, COVID-19, The Journal of Finance, Elasticity, Bias, Classification, Overalls, LTR, Credit, MFI, Literature, Creditor, Public sector, FX, UBB, Section 2, European Central Bank, EUR, C23, Pressure, LOLR, Chapter Two, Section 5, MPO, Rest, Reproduction, Website, Fahd of Saudi Arabia, RHS, Abstract, LCR, Capital Requirements Regulation 2013, National bank, Government, Interval (mathematics), Security (finance)
Key Points: 

    Monetary asmmetries without (and with) price stickiness

    Retrieved on: 
    Friday, April 19, 2024
    Online, University, Public Security Section 9, Employment, Calibration, Small, Equity, Volume Ten, Research Papers in Economics, Policy, A.4, Communication, Crisis, Mass, Silvana Tenreyro, Business, Shock, Intuition, Business cycle, TFP, Volume, European Economic Review, Marginal value, SME, NBER, Forecasting, Depression, 3rd millennium, European Economic Association, Conceptual model, Journal of Monetary Economics, Insurance, Harmonization, Great Depression, CES, Economic Inquiry, Paper, Environment, Political economy, Journal of Financial Economics, MIT, University of York, COVID-19, Behavior, Review of Economic Dynamics, Rigid transformation, Website, Access to finance, Accounting, Working paper, Probability, Total, Appendix, Section 8, Quarterly Journal of Economics, Zero lower bound, Curve, Chapter, Cost, Nominal, Journal of Political Economy, Euro, PDF, ECB, Unemployment, Hoarding, STAT, Economic Policy (journal), Household, Canadian International Council, Social science, Government, Federal Reserve Bank, JEL, Journal, Textbook, Missing, Food, Private sector, A.5, Asymmetric, The Journal of Finance, Credit, Speech, Princeton University Press, Literature, NK, European Central Bank, Growth, Labour, Monetary economics, Loss aversion, Financial intermediary, Injection, Elasticity, Inventory, Subprime lending, Ben Bernanke, Finance, BIS, Phillips curve, International Economic Review, Money, London School of Economics, Marginal product of labor, Pruning, Marginal product, The Economic Journal, Rate, Aswath Damodaran, Risk, OECD, Competition (economics), Section 4, MIT Press, Consumption, Bond, Section 3, Yield curve, Loanable funds, Habit, Cobb–Douglas production function, Economy, Aarhus University, Financial economics, Section 2, Conference, Central bank, Chapter Two, Monetary policy, Capital, Hartman–Grobman theorem, CEPR, Framework, American Economic Review, Capital Markets Union, ZLB, Exercise, Liquidity, Interest, Intensive word form, Workshop, European Commission, Macroeconomic Dynamics, Population growth, B1, Response, Quarterly Journal, Community business development corporation, GDP, E31, Control, Journal of Economic Theory, Christian Social Union (UK), T2M, Hamper, Data, American Economic Journal, Aggregate, Konstantinidis, B.1, A.9, A.6, Remuneration, Civil service commission, EUR, Uncertainty, Motivation, A.7, Bank, GFC, Section 13, Motion, Reproduction, IMF, Staggers Rail Act, Abstract, Tale, Handbook, Asymmetry, Stanford University, Communications satellite
    Key Points: 

      Digital euro safeguards – protecting financial stability and liquidity in the banking sector

      Retrieved on: 
      Thursday, April 18, 2024
      Central bank, Face, Finance, SUP, HSBC Finance, Digital currency, Frankfurt, Calibration, BIS, Sis, Research Papers in Economics, Excess, Meller, Statistics, PDF, ECB, Blog, Risk, Committee, Learning, Policy, Community business development corporation, Bank, Bank of Canada, Privacy, Social science, Eurosystem, Abstract, Consumption, JEL, SPACE, European Central Bank, Journal, CBDC, Journal of Monetary Economics, Interplay, Private sector, HFCS, Economy, Publication, ISSN, Usher, Conference, Environment, European Parliament, Monetary economics, Household, Reproduction, CEPR, Cournot, LCR, LCRS, M.E

      A digital euro would offer a wide range of

      Key Points: 
        • A digital euro would offer a wide range of
          financial stability benefits, including safeguarding the role of public money and
          strengthening the strategic autonomy and monetary sovereignty of the euro area in
          the digital era.
        • Keywords: CBDC, digital euro, bank intermediation, financial stability risks.
        • A digital euro has the potential to offer a wide range of financial stability
          benefits for the digital era.
        • A digital euro would
          stimulate financial innovation among private sector entities and enhance the
          efficiency and resilience of the financial system by supporting competition and
          diversity within it.3 In addition, a digital euro would strengthen the strategic autonomy
          and monetary sovereignty of the euro area.
        • A digital euro would be designed to minimise risks to the financial system.
        • 2

          The preparation phase will pave the way for a future decision on whether or not to issue a digital euro.

        • When gauging the implications for the euro area banking sector of introducing a
          digital euro, take-up would be key, as it would determine the level of deposit
          outflows.
        • In the latter case, the
          issuance of a digital euro would not affect banks? balance sheets, since banks would return euro
          banknotes to the Eurosystem in exchange for digital euro.
        • Banknotes and digital euro are two different
          types of central bank liability, so a swap between banknotes and digital euro would only affect the
          composition and not the size of the Eurosystem?s balance sheet.
        • In our analysis, we model only the
          substitution of commercial bank deposits with a possible future digital euro.
        • 8

          The legislative proposal on a digital euro provides for the inclusion of such safeguards and establishes
          specific criteria for the limits, aiming to contain the use of a digital euro as a store of value.

        • ECB Occasional Paper Series No 346

          4

          2

          The added value of digital euro
          safeguards such as holding limits
          To understand the benefits of digital euro safeguards, such as holding limits, it
          is useful to first consider the implications of introducing a CBDC without
          adequate safeguards.

        • (2022), ?Central bank digital currency and bank intermediation: Exploring different
          approaches for assessing the effects of a digital euro on euro area banks?, Occasional Papers, No 293,
          European Central Bank, Frankfurt am Main, May.
        • deciding to adopt the digital euro, and (ii) the average amount of digital euro in a
          wallet.
        • At the same time, as discussed in this paper, the design of a digital euro would
          include effective safeguards, such as individual holding limits, to mitigate
          potential financial stability risks.
        • ECB Occasional Paper Series No 346

          15

          an upper bound on the amount of digital euro in circulation, thereby addressing and
          limiting financial stability concerns associated with the introduction of a digital euro.

        • (2023), ?A digital euro: gauging the
          financial stability implications?, Financial Stability Review, ECB, November.

      EQS-News: Abivax reports 2023 financial results and operational update

      Retrieved on: 
      Wednesday, April 10, 2024
      Q&A, Nomination, New Drug Application, Patient, Shanda, MRO, G&A, IND, EQT, Marketing, Research, EST, McKinsey & Company, Carcinoma, Schering-Plough, Partnership, Webcast, SVP, IBD, Inflammatory Bowel Diseases, American College, Safety, Phase 10, Compensated emancipation, BB Biotech, URD, IPO, F2G, Sofinnova, FDA, AbbVie, EUR, Abstract, Takeda, Pharmaceutical industry

      Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.

      Key Points: 
      • Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.
      • Cash position (including other financial assets of EUR 9.0M) at the end of 2023 was EUR 261.0M, compared to EUR 27.0M at the end of 2022.
      • A webcast will be organized on Monday, April 8, 2024, at 2:30 p.m. CEST (8:30 a.m. EST) following the announcement of the 2023 yearly results.
      • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.

      Epic Bio Announces Robust Slate of Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

      Retrieved on: 
      Tuesday, April 9, 2024
      Poster, SAN, Cell, Abstract, Baltimore Convention Center, Gene, FSHD, Ballroom, Society, Convention, Dentistry

      SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Epic Bio , a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced the acceptance of six abstracts, three oral presentations, and three poster presentations at the upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland.

      Key Points: 
      • SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Epic Bio , a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced the acceptance of six abstracts, three oral presentations, and three poster presentations at the upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland.
      • Location: Baltimore at the Baltimore Convention Center, Ballroom 1, Baltimore, Maryland
        Location: Baltimore at the Baltimore Convention Center, Ballroom III, Baltimore, Maryland
        Location: Baltimore at the Baltimore Convention Center, Ballroom III, Baltimore, Maryland
        Location: Baltimore at the Baltimore Convention Center, Exhibit Hall, Baltimore, Maryland
        Location: Baltimore at the Baltimore Convention Center, Exhibit Hall, Baltimore, Maryland

      Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

      Retrieved on: 
      Monday, April 8, 2024
      Ovarian cancer, Cetuximab, CRDF, RAS, Patient, Bev, PLK1, Abstract, AACR, Bevacizumab, Cancer, Phase, Data, SCLC, Pharmaceutical industry

      In combination, the abstracts underscore the significant potential of the company’s lead molecule onvansertib in metastatic colorectal cancer (mCRC) and other cancers.

      Key Points: 
      • In combination, the abstracts underscore the significant potential of the company’s lead molecule onvansertib in metastatic colorectal cancer (mCRC) and other cancers.
      • In addition, we are particularly encouraged by our RAS-mutated mCRC preclinical data highlighting onvansertib’s ability to inhibit activation of the hypoxia pathway via the regulation of HIF1α.
      • All the abstracts are available on the AACR Online Program and will be published in the online Proceedings of the AACR.
      • Following the presentation, the posters will be posted to the “ Scientific Presentations ” section of the Cardiff Oncology website.

      Actuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting

      Retrieved on: 
      Monday, April 8, 2024
      Abstract, AACR, Actuate, Therapy

      CHICAGO and FORT WORTH, Texas, April 08, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today two poster presentations from scientific collaborators at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, California.

      Key Points: 
      • CHICAGO and FORT WORTH, Texas, April 08, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today two poster presentations from scientific collaborators at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, California.
      • The abstracts are currently available on the AACR meeting website .
      • The posters will be available online at https://actuatetherapeutics.com/news-media/ following the presentations.

      Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

      Retrieved on: 
      Friday, April 5, 2024
      HLE, Abstract, PDT, TME, CD8, Perforin-1, Tumor microenvironment, Cancer, AACR, Phenotype, Neoplasm, Therapy, Section 4, Granzyme, NK, Poster, Vaccine

      WATERTOWN, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally-activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, is presenting preclinical data on development candidates WTX-518 and WTX-712 in posters at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.

      Key Points: 
      • “We are excited to share that both WTX-518 and WTX-712 demonstrate powerful immunotherapeutic effects in preclinical models,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf.
      • “WTX-518 exhibits remarkable tumor-selective activation, resistance to IL-18BP and robust immune activation, overcoming key hurdles in the use of this promising cytokine in cancer therapy.
      • WTX-712 acts through a unique mechanism that robustly activates tumor-specific T lymphocytes with an expanded therapeutic window through its selective release of wild-type IL-21 in the TME.
      • Werewolf plans to develop WTX-518 and WTX-712 as potential immunotherapies in refractory and/or immunologically unresponsive tumors.

      HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366

      Retrieved on: 
      Friday, April 5, 2024
      SOC, EGFR, GCN2, NSCLC, Journal, Abstract, AACR, Publication, Therapy, Metastasis, Medicinal chemistry, Pharmaceutical industry

      This publication and abstracts are now available online and on the AACR website, respectively.

      Key Points: 
      • This publication and abstracts are now available online and on the AACR website, respectively.
      • Our first poster features the remarkable preclinical activity of HC-7366 as monotherapy and in combination with belzutifan in clear cell renal cell carcinoma models (ccRCC).
      • This work was foundational to our ongoing Phase 1b study in ccRCC in combination with belzutifan, which was announced earlier this year.
      • Abstract Title: HC-7366, a potent GCN2 kinase activator, augments osimertinib therapy to delay resistance in EGFR mutant NSCLC models.

      Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

      Retrieved on: 
      Thursday, April 4, 2024
      Safety, CIIC, Abstract, HAE, Hereditary angioedema, Conference, Bradykinin receptor B2, Pharmaceutical industry

      ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX.

      Key Points: 
      • ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX.
      • Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
        The posters and associated presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentation sessions at: https://ir.pharvaris.com/news-events/events-presentations .